Healthcare entity
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. The 72-day window averages about 0.3 stories each week.
Last mentioned: Aug 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. The 72-day window averages about 0.3 stories each week. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. They are corroborated in line with the beat average, carrying 3.7 original sources each against 3.7 for the same window. Zepbound appears in 3 tracked Healthcare stories published from June 14, 2026 through August 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 531 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zepbound. Shared-story counts are live from our verified record — not editorial picks.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
80-week trial results released
Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.
Off-Label Drug Mandate
The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process.
Vida Health Assessment
Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse.
Employer Imposes Vida Health Requirement
Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits.
Zepbound Prescription Issued
David Davis receives a prescription for Zepbound from his primary care doctor to treat obstructive sleep apnea.
Rhythm Pharmaceuticals' Imcivree targets rare genetic obesity forms that GLP-1 leaders Eli Lilly and Novo Nordisk don't treat. With a U.S.-Europe market of up to 7,500 patients and a new Druckenmiller-backed position, healthcare stakeholders are watching a distinct orphan drug niche.
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
A California man’s employer-mandated use of Vida Health stalled his Zepbound treatment for obstructive sleep apnea, highlighting how telehealth platforms are overriding primary care physicians to reduce obesity drug costs.
Zepbound is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
